07 November 2022
EMA/CHMP/816076/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 07-10 November 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

07 November 2022, 13:00 – 19:30, virtual meeting/room 1C

08 November 2022, 08:30 – 19:30, virtual meeting/room 1C

09 November 2022, 08:30 – 19:30, virtual meeting/room 1C

10 November 2022, 08:30 – 15:00, virtual meeting/room 1C

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 07-10 November 2022. See November 2022 CHMP minutes (to be published post December 2022 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 07-10 November 2022.

1.3. Adoption of the minutes

CHMP minutes for 10-13 October 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 31 October 2022.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. miglustat - Orphan - EMEA/H/C/005695

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: Possible oral explanation

Action: Oral explanation to be held on 09 November 2022 at 11:00

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 24.03.2022.

2.1.2. cipaglucosidase alfa - Orphan - EMEA/H/C/005703

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: Possible oral explanation

Action: Oral explanation to be held on 09 November 2022 at 09:00

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 24.03.2022.

2.1.3. iodine (131I) omburtamab - Orphan - EMEA/H/C/005499

Y-Mabs Therapeutics A/S; treatment of neuroblastoma

Scope: Oral explanation

Action: Oral explanation to be held on 08 November 2022 at 14:00

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 16.09.2021.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Eylea - aflibercept - EMEA/H/C/002392/II/0077/G

Bayer AG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault

Scope: "C.I.6 (Extension of indication) Extension of indication to include the paediatric indication retinopathy of prematurity (ROP) for Eylea; as a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Separate Package Leaflet is proposed for the guardians of preterm babies. Version 32.1 of the RMP has also been submitted. B.IV.1.a.3."

Oral explanation

Action: Oral explanation to be held on 09 November 2022 at 14:00

Request for Supplementary Information adopted on 13.10.2022, 24.02.2022.

See 5.1

2.3.2. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0012

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu based on final results from studies DS8201 A J202 (DESTINY Gastric01) and DS8201-A-U205 (DESTINY Gastric02); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Oral explanation

Action: Oral explanation to be held on 09 November 2022 at 16:00

Request for Supplementary Information adopted on 23.06.2022, 27.01.2022.

See 5.1

2.4. Referral procedure oral explanations

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. teriparatide - EMEA/H/C/004932

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022, 16.12.2021. List of Questions adopted on 28.01.2021.

3.1.2. pirfenidone - EMEA/H/C/005862

treatment of Idiopathic Pulmonary Fibrosis (IPF)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 24.03.2022.

3.1.3. sugammadex - EMEA/H/C/005935

reversal of neuromuscular blockade induced by rocuronium or vecuronium
Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 24.03.2022.

3.1.4. SARS-CoV-2 prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754

Active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 13.10.2022. List of Questions adopted on 20.06.2022.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. sodium phenylbutyrate / ursodoxicoltaurine - Orphan - EMEA/H/C/005901

Amylyx Pharmaceuticals EMEA B.V.; treatment of amyotrophic lateral sclerosis (ALS)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2022.

3.2.2. dapagliflozin - EMEA/H/C/006006

treatment of type 2 diabetes mellitus, heart failure and chronic kidney disease

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2022.

3.2.3. pegunigalsidase alfa - Orphan - EMEA/H/C/005618

Chiesi Farmaceutici S.p.A.; treatment of Fabry disease

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2022.

3.2.4. gadopiclenol - EMEA/H/C/005626

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2022.

3.2.5. sirolimus - Orphan - EMEA/H/C/005896

Plusultra pharma GmbH; Treatment of angiofibroma associated with tuberous sclerosis

complex

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2022.

3.2.6. bardoxolone methyl - Orphan - EMEA/H/C/005869

Reata Ireland Limited; treatment of chronic kidney disease

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

3.2.7. tremelimumab - Orphan - EMEA/H/C/006016

AstraZeneca AB; For use in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 21.07.2022.

3.2.8. daprodustat - EMEA/H/C/005746

treatment of anaemia associated with chronic kidney disease (CKD) in adults

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2022.

3.2.9. spironolactone - EMEA/H/C/005535

Management of refractory oedema

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

3.2.10. sitagliptin / metformin hydrochloride - EMEA/H/C/005778

treatment of type 2 diabetes mellitus

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.06.2022.

3.2.11. gadopiclenol - EMEA/H/C/006172

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

Scope: List of outstanding issues

Action: For adoption

3.2.12. filgrastim - EMEA/H/C/005888

Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection

Scope: List of outstanding issues; Letter by the applicant dated 25.10.2022 requesting an extension to the clock stop to respond to the list of outstanding issues.

Action: For adoption

List of Questions adopted on 23.06.2022.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. piflufolastat (18f) - EMEA/H/C/005520

imaging in patients undergoing oncologic diagnostic procedures when increased expression of prostate specific membrane antigen is a diagnostic target

Scope: List of questions

Action: For adoption

3.3.2. dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009

Norgine B.V.; treatment of malignant hyperthermia (including suspected cases)

Scope: List of questions

Action: For adoption

3.3.3. degarelix acetate - EMEA/H/C/006048

treatment of prostate cancer

Scope: List of questions

Action: For adoption

3.3.4. trastuzumab duocarmazine - EMEA/H/C/005654

treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast

cancer

Scope: List of questions

Action: For adoption

3.3.5. eculizumab - EMEA/H/C/006036

treatment of paroxysmal nocturnal haemoglobinuria

Scope: List of questions

Action: For adoption

3.3.6. natalizumab - EMEA/H/C/005752

Therapy for active relapsing remitting multiple sclerosis (RRMS)

Scope: List of questions

Action: For adoption

3.3.7. alpelisib - Orphan - EMEA/H/C/005468

Novartis Europharm Limited; treatment of patients with severe manifestations of PIK3CA-related overgrowth spectrum

Scope: List of questions

Action: For adoption

3.3.8. atogepant monohydrate - EMEA/H/C/005871

Prophylaxis of migraine in adults who have at least 4 migraine days per month.

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

No items

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. infigratinib - Orphan - EMEA/H/C/005361

Helsinn Birex Pharmaceuticals Limited; treatment of cholangiocarcinoma

Scope: Withdrawal of marketing authorisation application

Action: For information

List of Questions adopted on 24.03.2022.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 1 year and above). The paediatric indication is applicable to the new presentation (2 mg/ml granules for oral suspension) as well as all approved presentations (EU/1/20/1500/001 and 002).
The RMP (version 2.0) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 22.04.2022.

4.1.2. Comirnaty - tozinameran - EMEA/H/C/005735/X/0147

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add a new strength of 5/5 µg (tozinameran, famtozinameran) for children between 5 to 11 years of age. The RMP (version 7.2) is updated in accordance."

Action: For adoption

4.1.3. Comirnaty - tozinameran - EMEA/H/C/005735/X/0138

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add a new strength of 3 µg for individuals 6 months to 4 years of age. In addition, the applicant took the opportunity to introduce editorial changes in Annex I, IIIA and IIIB of the PI. The RMP (version 5.1) is updated in accordance."

Positive opinion adopted by consensus at the extraordinary meeting held on 19 October 2022.

Action: For information

Request for Supplementary Information adopted on 13.10.2022.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Byfavo - remimazolam - EMEA/H/C/005246/X/0002

Paion Deutschland GmbH

Rapporteur: Bruno Sepodes, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (50 mg powder for concentrate for solution for injection/infusion). The new presentation is indicated to include the intravenous induction and maintenance of general anesthesia (GA) in adults for Byfavo 50 mg, based on final results from two pivotal trials: Study ONO-2745-05, a phase IIb/III, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in ASA I/II patients (general surgery), and study CNS-7056-022, a phase III, randomized, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients.
A new combined version of the SmPC, labelling and Package Leaflet solely for the 50 mg strength and the GA indication is provided accordingly. Version 1.1 of the RMP has also been submitted. As part of the application, the MAH also requests an extension of the market protection by one additional year."

Action: For adoption

List of Questions adopted on 19.05.2022.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Entresto - sacubitril / valsartan - EMEA/H/C/004062/X/0044/G

Novartis Europharm Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension application to introduce a new pharmaceutical form associated with two new strengths (6 mg/6 mg granules in capsule for opening and 15 mg/16 mg granules in capsule for opening), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of children and adolescents aged one year or older with chronic heart failure with left ventricular systolic dysfunction, based on the results of study PANORAMA-HF (CLCZ696B2319); a multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of sacubitril/valsartan followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of sacubitril/valsartan compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.2 of the SmPC are being updated and the Package Leaflet is updated accordingly. In addition, an updated RMP version 4.0 was provided as part of the application. Further, the MAH requested a one year extension of the market protection."

Action: For adoption

4.3.2. Neparvis - sacubitril / valsartan - EMEA/H/C/004343/X/0042/G

Novartis Europharm Limited

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension application to introduce a new pharmaceutical form associated with two new strengths (6 mg/6 mg granules in capsule for opening and 15 mg/16 mg granules in capsule for opening), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of children and adolescents aged one year or older with chronic heart failure with left ventricular systolic dysfunction, based on the results of study PANORAMA-HF (CLCZ696B2319); a multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of sacubitril/valsartan followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of sacubitril/valsartan compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.2 of the SmPC are being updated and the Package Leaflet is updated accordingly. In addition, an updated RMP version 4.0 was provided as part of the application. Further, the MAH requested a one year extension of the market protection."

Action: For adoption

4.3.3. Sogroya - somapacitan - Orphan - EMEA/H/C/005030/X/0006/G

Novo Nordisk A/S

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber

Scope: "Extension application to add a new strength of 15 mg/1.5 mL solution for injection in pre-filled pen grouped with a type II variation C.I.6 to add a new indication 'Replacement of endogenous growth hormone (GH) in children and adolescents with growth failure due to growth hormone deficiency (GHD)', based on results from the completed main 52-week period of the confirmatory phase 3 trial (4263), supported with long-term data from the phase 2 trial (4172), up to week 208 completed. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. A revised RMP version 3.0 was provided as part of the application."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Ultomiris - ravulizumab - EMEA/H/C/004954/X/0027/G

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola

Scope: Letter by the applicant dated 27.10.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in October 2022.

Action: For adoption

List of Outstanding Issues adopted on 13.10.2022. List of Questions adopted on 21.07.2022.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Ceprotin - human protein c - EMEA/H/C/000334/II/0127

Takeda Manufacturing Austria AG

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include long-term prophylaxis (deletion of wording 'short-term' and currently listed conditions) of purpura fulminans and coumarin induced skin necrosis in patients with severe congenital protein C deficiency, based on a re-analysis of long-term prophylaxis data from the pivotal study 400101; a phase 2/3 clinical study undertaken to evaluate PK, safety and efficacy of CEPROTIN in patients with severe congenital PC deficiency for the treatment of acute thrombotic episodes, for short-term thromboembolic prophylaxis and for long-term prophylactic treatment. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet.
Version 2.0 of the RMP has also been submitted. In addition, MAH took the opportunity to correct the address of the manufacturer of the biological active substance in Annex II following variation EMEA/H/C/000334/IAIN/0126/G."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.2. Dupixent - dupilumab - EMEA/H/C/004390/II/0062

Sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy, based on the pivotal study R668-EE-1774. This is an ongoing phase 3, randomized, double-blind, placebo-controlled, 3-part (A, B, C) safety and efficacy study with an initial 24-week treatment period in adults (≥18 years of age) and adolescents (≥12 to <18 years of age) with EoE, and which includes an extended treatment period to a total of 52 weeks. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.3. Dupixent - dupilumab - EMEA/H/C/004390/II/0063

Sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adults with moderate to severe prurigo nodularis (PN) who are candidates for systemic therapy, based on results from studies EFC16459 and EFC16460 (PRIME and PRIME2); these are two phase 3, 24-week, randomized, double-blind, placebo-controlled, multi-centre, parallel group studies undertaken to evaluate the efficacy and safety of dupilumab in patients 18 years of age and

older with moderate to severe PN, who are inadequately controlled on topical prescription therapies or when those therapies are not advisable. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted.
As part of this application, the MAH is also requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.4. Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0012

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu based on final results from studies DS8201 A J202 (DESTINY Gastric01) and DS8201-A-U205 (DESTINY Gastric02); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022, 27.01.2022.

See 2.3

5.1.5. Ervebo - recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0025

Merck Sharp & Dohme B.V.

Rapporteur: Christophe Focke, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the paediatric population from 1 year to less than 18 years of age based on final results from study V920-016 (PREVAC); this is a phase 2, randomized, double-blind, placebo-controlled study of 2 leading Ebola vaccine candidates (Ad26.ZEBOV/MVA-BN-Filo and V920) and 3 vaccine strategies (Ad26.ZEBOV/MVABN-Filo, 1-dose V920, and 2 dose V920) to evaluate immunogenicity and safety in healthy children and adolescents from 1 to 17 years of age and adults 18 years of age and older. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the Annex II and the list of local representatives in the Package Leaflet."

Action: For adoption

5.1.6. Eylea - aflibercept - EMEA/H/C/002392/II/0077/G

Bayer AG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault

Scope: "C.I.6 (Extension of indication) Extension of indication to include the paediatric indication retinopathy of prematurity (ROP) for Eylea; as a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Separate Package Leaflet is proposed for the guardians of preterm babies. Version 32.1 of the RMP has also been submitted. B.IV.1.a.3."

Action: For adoption

Request for Supplementary Information adopted on 13.10.2022, 24.02.2022.

See 2.3

5.1.7. Iclusig - ponatinib - Orphan - EMEA/H/C/002695/II/0064

Incyte Biosciences Distribution B.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of newly diagnosed adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), either with Iclusig (ponatinib) in combination with chemotherapy, or with Iclusig (ponatinib) monotherapy after corticosteroid induction in patients not eligible to receive chemotherapy-based regimens, based on final results from studies AP24534-11-001 and INCB 84344-201. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22 of the RMP has also been submitted."

Action: For adoption

5.1.8. Imfinzi - durvalumab - EMEA/H/C/004771/II/0045

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Imfinzi in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from study D419CC00002 (HIMALAYA); This was a randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 6.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.9. Imfinzi - durvalumab - EMEA/H/C/004771/II/0046

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Imfinzi in combination with chemotherapy for the treatment of adults with locally advanced or metastatic biliary tract cancer (BTC), based on the second interim analysis from the ongoing pivotal study D933AC00001 (TOPAZ-1); a phase III randomized, double-blind, placebo-controlled, multi-regional, international study conducted to assess the efficacy and safety of durvalumab in combination with the current standard of care Gemcitabine/Cisplatin for the first-line treatment of patients with locally advanced or metastatic BTC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. Version 7.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 13.10.2022, 21.07.2022.

5.1.10. Lynparza - olaparib - EMEA/H/C/003726/II/0053

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone, based on the results of the pivotal Phase III study PROpel (D081SC00001) and supportive evidence from study 8 (D081DC00008). PROpel is a Phase III, randomised, double-blind, placebo-controlled, multicentre study evaluating olaparib vs placebo in combination with abiraterone as first line treatment for men with mCRPC. Consequently, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC for Lynparza tablets are being updated. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on the updated safety data analysis. The Package Leaflet is updated accordingly. The RMP version 24 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 13.10.2022, 21.07.2022, 22.04.2022.

5.1.11. Reblozyl - luspatercept - Orphan - EMEA/H/C/004444/II/0009

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Daniela Philadelphy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Jo Robays

Scope: "C.I.6 (Extension of indication)
Extension of indication in β-thalassaemia to include adult patients with non-transfusion dependent β-thalassaemia (NTDT) for Reblozyl; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation

holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022, 27.01.2022.

5.1.12. Rinvoq - upadacitinib - EMEA/H/C/004760/II/0027

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include treatment of moderately to severely active Crohn's disease in adult patients for Rinvoq, based on final results from three Phase III studies, two confirmatory placebo-controlled induction studies (study M14 431/U-EXCEED/CD-1) and study M14 433/U-EXCEL/CD-2) and a placebo-controlled maintenance/long-term extension study (study M14-430/U-ENDURE/CD-3).
M14-431 study is a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy.
M14-433 study is a Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies.
M14-430 study is an ongoing Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease Who Completed the Studies M14-431 or M14-433.
As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted."

Action: For adoption

5.1.13. Spikevax - elasomeran - EMEA/H/C/005791/II/0067

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include immunisation of paediatric individuals from 6 months through 5 years of age based on results from the study P204 (KidCove); this is a phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. The MAH also took the opportunity to implement minor editorial changes in the product information. A revised RMP version 4.1 has been approved."

Positive opinion adopted by consensus at the extraordinary meeting held on 19 October 2022.

Action: For information

Request for Supplementary Information adopted on 13.10.2022, 23.06.2022.

5.1.14. Spikevax - elasomeran - EMEA/H/C/005791/II/0083/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include a 50-µg booster dose of Spikevax bivalent Original/Omicron BA.1 in children (6 to < 12 years), based on interim results from study P204; this is a Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age; As a consequence, sections 2, 4.1, 4.2, 4.4, 4.8, 5.1 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.5 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes.
To update sections 4.8, 5.1 and 6.6 of the SmPC to include additional immunogenicity data for the paediatric population (6 to < 18 years) based on Real-World Safety studies."

Action: For adoption

5.1.15. Trecondi - treosulfan - Orphan - EMEA/H/C/004751/II/0014

Medac Gesellschaft fur klinische Spezialpraparate mbH

Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos

Scope: "Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases.
Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.16. WS2150
DuoPlavin - clopidogrel / acetylsalicylic acid - EMEA/H/C/001143/WS2150/0060
Iscover - clopidogrel - EMEA/H/C/000175/WS2150/0146
Plavix - clopidogrel - EMEA/H/C/000174/WS2150/0145

Sanofi-aventis groupe

Lead Rapporteur: Bruno Sepodes, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include clopidogrel in combination with acetylsalicylic acid in ST segment elevation acute myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI); as a consequence, section 4.1, 4.2 and 5.1 of the SmPC is updated. Version 1.5 of the RMP has also been submitted. In addition, an editorial update has been made to the labelling."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022, 24.03.2022.

5.1.17. WS2299
Edistride - dapagliflozin - EMEA/H/C/004161/WS2299/0055
Forxiga - dapagliflozin - EMEA/H/C/002322/WS2299/0076

AstraZeneca AB

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include population with Heart Failure and LVEF > 40% for Forxiga and its duplicate Edistride, based on final results from study D169CC00001 (DELIVER); The DELIVER study is a category 3, Post-Authorisation Safety Study (PASS) listed in the dapagliflozin RMP to evaluate the potential risk of lower limb amputation; This was an international, multi-centre, parallel-group, event-driven, randomised, double-blind, placebo-controlled Phase III study in patients with HF and LVEF > 40%, evaluating the effect of dapagliflozin 10 mg compared with placebo, given once daily in addition to background therapy, including treatments to control co-morbidities, in reducing the composite of CV death or an HF event (hospitalisation for HF or urgent HF visit). As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet are updated in accordance. Version 27 of the RMP has also been submitted."

Action: For adoption

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

6.1.1. human albumin solution / gentamicin sulfate - EMEA/H/D/006141

human assisted reproductive techniques including in-vitro fertilisation procedures

Scope: Day 120 list of questions

Action: For adoption

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

No items

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. talquetamab - Orphan - PRIME - H0005864

Janssen-Cilag International N.V., indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.1.2. beremagene geperpavec - Orphan - ATMP – PRIME - H0005350

Krystal Biotech, Inc., Dystrophic Epidermolysis Bulbosa

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0003

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola

"Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to change the posology recommendations in the pre-exposure prophylaxis indication based on study TACKLE (D8851C00001). The Package Leaflet is updated accordingly. The RMP version 2 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 13.10.2022.

9.1.2. Jcovden - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0053/G

Janssen-Cilag International N.V.

Rapporteur: Christophe Focke

Scope: "Update of section 4.2 of the SmPC to introduce an heterologous booster dose of Jcovden following priming with another adenoviral vector-based vaccine and an inactivated whole virion COVID-19 vaccine based on literature evidence from studies COV-BOOST and RHH-01, respectively. Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of Jcovden as homologous and heterologous booster dose based on data from studies COV2008, a randomised, double-blind Phase 2 Study and literature evidence from studies COV-BOOST, RHH-001 and DMID 21-0012. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

9.1.3. Spikevax - elasomeran - EMEA/H/C/005791/II/0084/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: B.I.a.6.a (Type II): Addition of a new strain (Omicron BA.4-5) resulting in a new Spikevax bivalent Original/Omicron BA.4-5 (50 µg elasomeran/50 µg davesomeran)/mL 0.1 mg/mL dispersion for injection presentation. The Annex A, the SmPC, the Annex II, the labelling and the Package Leaflet are updated accordingly.

Positive opinion adopted by consensus at the extraordinary meeting held on 19 October 2022.

Action: For information

9.1.4. Hepsera - adefovir dipivoxil – EMEA/H/C/000485

Gilead Sciences Ireland UC; treatment of hepatitis B

Rapporteur: Jean-Michel Race, Co-Rapporteur: Thalia Marie Estrup Blicher

Scope: Withdrawal of marketing authorisation

Action: For information

9.1.5. Ilaris - canakinumab - EMEA/H/C/001109/II/0075

Novartis Europharm Limited

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with Schnitzler syndrome for Ilaris; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted."

Withdrawal of application of extension of indication

Action: For information

Request for Supplementary Information adopted on 19.05.2022, 11.11.2021.

9.1.6. Zejula - niraparib - EMEA/H/C/004249/II/0033, Orphan

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: "Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning and add MDS/AML to the list of adverse drug reactions (ADRs) with frequency common and update of section 5.1 based on final results from NOVA study (213356); this is a Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. In addition, the MAH also took this opportunity to update sections 4.4 and 4.6 to update information on contraception based on EMA and CTFG recommendations. The Package Leaflet is updated accordingly. The RMP version 6 has also been submitted."

Update on the status of this application.

Action: For information

Request for Supplementary Information adopted on 19.05.2022, 10.02.2022.

9.1.7. Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, some minor changes to the PI have been implemented in line with the latest Anticancer Guidelines Recommendations. Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Withdrawal of application of extension of indication

Action: For information

Request for Supplementary Information adopted on 15.09.2022, 23.06.2022, 24.03.2022.

9.1.8. Trogarzo – ibalizumab – EMEA/H/C/004961

Theratechnologies Europe Limited; treatment of adults infected with HIV-1 resistant to at least 1 agent in 3 different classes

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Armando Genazzani

Scope: Withdrawal of marketing authorisation

Action: For information

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. Janus kinase (JAK) inhibitors[1]: abrocitinib - CIBINQO (CAP); baricitinib - OLUMIANT (CAP); filgotinib - JYSELECA (CAP); tofacitinib - XELJANZ (CAP); upadacitinib - RINVOQ (CAP) – EMEA/H/A-20/1517

AbbVie Deutschland GmbH & Co. KG (Rinvoq), Eli Lilly Nederland B.V. (Olumiant), Galapagos N.V. (Jyseleca), Pfizer Europe MA EEIG (Cibinqo, Xeljanz)

Referral PRAC Rapporteur: Ulla Wändel Liminga; Referral PRAC Co-rapporteur(s): Liana Gross-Martirosyan (Olumiant, Xeljanz), Nikica Mirošević Skvrce (Cibinqo, Jyseleca, Rinvoq)

Scope: Review of the benefit-risk balance following notification by the European Commission (EC) of a referral under Article 20 of Regulation (EC) No 726/2004, based on pharmacovigilance data

Action: For adoption

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Gelisia - EMEA/H/A-29(4)/1522

Sifi S.p.A.

Rapporteur: TBC, Co-Rapporteur: TBC

Scope: Appointment of Rapporteurs, List of Questions, Timetable

Action: For adoption

Decentralised procedure number: NL/H/5357/001/DC, notification by the Agency of the Netherlands dated 22 October 2022 notifying of the start of a referral under Article 29(4) of

[1] Indicated for the treatment of inflammatory disorders

Directive 2001/83/EC

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

November 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

No items

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for November 2022

Action: For adoption

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at November 2022 PDCO

Action: For information

Report from the PDCO meeting held on 08-11 November 2022

Action: For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/ Sean Barry

Reports from the BWP 31 October 2022 meeting to CHMP for adoption

Action: For adoption

14.3.2. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 15-16 November 2022.

Action: For adoption

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 24-27 October 2022. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.4. Non-clinical Working Party (NcWP)

CHMP request for NcWP consultation on nitrosamine impurity.

Action: For adoption

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

09 January 2023 Corr.1[1]
EMA/CHMP/824637/2022

Annex to 07-10 November 2022 CHMP Agenda

Pre-submission and post-authorisations issues

[1] Correction in section B.4

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for November 2022: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for November 2022: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Atriance - nelarabine - EMEA/H/C/000752/S/0058
Novartis Europharm Limited, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Imvanex - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/S/0077
Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Lojuxta - lomitapide - EMEA/H/C/002578/S/0052
Amryt Pharmaceuticals DAC, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Mepsevii - vestronidase alfa - EMEA/H/C/004438/S/0032, Orphan
Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur:

Alexandre Moreau, PRAC Rapporteur: Maria del Pilar Rayon

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Alofisel - darvadstrocel - EMEA/H/C/004258/R/0036, Orphan, ATMP

Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, Co-Rapporteur: Margarida Menezes-Ferreira, CHMP Coordinators: Kristina Dunder and Fátima Ventura, PRAC Rapporteur: Brigitte Keller-Stanislawski

Request for Supplementary Information adopted on 09.09.2022.

Amglidia - glibenclamide - EMEA/H/C/004379/R/0014, Orphan

Ammtek, Rapporteur: Martina Weise, PRAC Rapporteur: Maria del Pilar Rayon

Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/R/0052

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan

Fulvestrant Mylan - fulvestrant - EMEA/H/C/004649/R/0016

Mylan Pharmaceuticals Limited, Generic, Generic of Faslodex, Rapporteur: Elita Poplavska, PRAC Rapporteur: Ulla Wändel Liminga

Request for Supplementary Information adopted on 15.09.2022.

Juluca - dolutegravir / rilpivirine - EMEA/H/C/004427/R/0049

ViiV Healthcare B.V., Rapporteur: Janet Koenig, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Nathalie Gault

Kanjinti - trastuzumab - EMEA/H/C/004361/R/0022

Amgen Europe B.V., BREDA, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea

Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski

Lamzede - velmanase alfa - EMEA/H/C/003922/R/0029, Orphan
Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Jan Neuhauser
Request for Supplementary Information adopted on 13.10.2022.

Prasugrel Mylan - prasugrel - EMEA/H/C/004644/R/0014
Mylan Pharmaceuticals Limited, Generic, Generic of Efient, Rapporteur: Alar Irs, PRAC Rapporteur: Anette Kirstine Stark

B.2.3. Renewals of Conditional Marketing Authorisations

Holoclar - ex vivo expanded autologous human corneal epithelial cells containing stem cells - EMEA/H/C/002450/R/0048, Orphan, ATMP
Holostem Terapie Avanzate s.r.l., Rapporteur: Egbert Flory, Co-Rapporteur: Concetta Quintarelli, CHMP Coordinators: Jan Mueller-Berghaus and Armando Genazzani, PRAC Rapporteur: Rhea Fitzgerald

Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/R/0023
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber
Request for Supplementary Information adopted on 13.10.2022.

Sirturo - bedaquiline - EMEA/H/C/002614/R/0050, Orphan
Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 24-27 October 2022
PRAC:

Signal of heavy menstrual bleeding

Comirnaty – tozinameran

Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst
PRAC recommendation on a variation
Action: For adoption

Signal of heavy menstrual bleeding

Spikevax – elasomeran

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Marie Louise Schougaard Christiansen
PRAC recommendation on a variation
Action: For adoption

Signal of myelitis transverse

Imfinzi – durvalumab

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen
PRAC recommendation on a variation
Action: For adoption

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its November 2022 meeting:

EMEA/H/C/PSUSA/00009327/202204
(vandetanib)
CAPS:
Caprelsa (EMEA/H/C/002315) (vandetanib), Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "07/04/2021 To: 06/04/2022"

EMEA/H/C/PSUSA/00010675/202203
(sodium zirconium cyclosilicate)
CAPS:
Lokelma (EMEA/H/C/004029) (sodium zirconium cyclosilicate), AstraZeneca AB, Rapporteur: Silvijus Abramavicius, PRAC Rapporteur: Kirsti Villikka, "22/03/2021 To: 21/03/2022"

EMEA/H/C/PSUSA/00010765/202203 (risankizumab) CAPS: **Skyrizi** (EMEA/H/C/004759) (risankizumab), AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy, PRAC Rapporteur: Liana Gross-Martirosyan, "25/03/2021 To: 25/03/2022"	
EMEA/H/C/PSUSA/00010818/202203 (siponimod) CAPS: **Mayzent** (EMEA/H/C/004712) (siponimod), Novartis Europharm Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Maria del Pilar Rayon, "26/09/2021 To: 25/03/2022"	
EMEA/H/C/PSUSA/00010900/202203 (cabotegravir) CAPS: **Vocabria** (EMEA/H/C/004976) (cabotegravir), ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "18/09/2021 To: 17/03/2022"	

B.4. EPARs / WPARs

Dengue Tetravalent Vaccine (Live, Attenuated) Takeda - dengue tetravalent vaccine (live, attenuated) - EMEA/H/W/005362, Article 58 Takeda GmbH, prevention of dengue disease, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Dimethyl fumarate Teva - dimethyl fumarate - EMEA/H/C/005963 TEVA GmbH, treatment of multiple sclerosis, Generic, Generic of TECFIDERA, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Ebvallo - tabelecleucel - EMEA/H/C/004577, Orphan, ATMP Atara Biotherapeutics Ireland Limited, treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV^+ PTLD), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Eladynos - abaloparatide - EMEA/H/C/005928 Radius Health Ireland Ltd, treatment of	For information only. Comments can be sent to the PL in case necessary.

osteoporosis, New active substance (Article 8(3) of Directive No 2001/83/EC)	
LIVMARLI - maralixibat - EMEA/H/C/005857, Orphan Mirum Pharmaceuticals International B.V., Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Locametz - gozetotide - EMEA/H/C/005488 Novartis Europharm Limited, indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Pemetrexed Baxter - pemetrexed - EMEA/H/C/005848 Baxter Holding B.V., treatment of malignant pleural mesothelioma and non-small cell lung cancer, Generic, Generic of Alimta, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Plerixafor Accord - plerixafor - EMEA/H/C/005943 Accord Healthcare S.L.U., treatment of lymphoma and multiple myeloma, Generic, Generic of Mozobil, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Pluvicto - lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483 Novartis Europharm Limited, treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Qdenga - dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155 Takeda GmbH, prevention of dengue disease, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Spevigo - spesolimab - EMEA/H/C/005874 Boehringer Ingelheim International GmbH, treatment of flares in adult patients with generalised pustular psoriasis, New active substance (Article 8(3) of Directive No	For information only. Comments can be sent to the PL in case necessary.

2001/83/EC)	
in vitro diagnostic medical device - EMEA/H/D/006107 In-vitro qualitative immunohistochemical detection of programmed death-ligand 1 (PD-L1), Companion Diagnostics (Article 48 (3), (4), (7), (8) of Regulation (EU) 2017/746)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0079/G GlaxoSmithkline Biologicals SA, Informed Consent of Pandemrix (EXP), Rapporteur: Johann Lodewijk Hillege Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.
AMGEVITA - adalimumab - EMEA/H/C/004212/II/0031 Amgen Europe B.V., Rapporteur: Kristina Dunder	
Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0007/G Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy Opinion adopted on 20.10.2022. Request for Supplementary Information adopted on 08.09.2022.	Positive Opinion adopted by consensus on 20.10.2022.
Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0161 Amgen Europe B.V., Rapporteur: Martina Weise Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 15.09.2022.	Positive Opinion adopted by consensus on 27.10.2022.
ARIKAYCE liposomal - amikacin - EMEA/H/C/005264/II/0008/G, Orphan Insmed Netherlands B.V., Rapporteur: Jayne Crowe Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.

Request for Supplementary Information adopted on 15.09.2022.	
Cosentyx - secukinumab - EMEA/H/C/003729/II/0092/G Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola Opinion adopted on 27.10.2022.	Positive Opinion adopted by consensus on 27.10.2022.
Doptelet - avatrombopag - EMEA/H/C/004722/II/0015/G Swedish Orphan Biovitrum AB (publ), Rapporteur: Aaron Sosa Mejia Request for Supplementary Information adopted on 27.10.2022.	Request for supplementary information adopted with a specific timetable.
Foclivia - prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/001208/II/0079 Seqirus S.r.l, Rapporteur: Armando Genazzani	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0051 AstraZeneca AB, Rapporteur: Aaron Sosa Mejia	
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0079 Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus	
Inflectra - infliximab - EMEA/H/C/002778/II/0108/G Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 20.10.2022.	Request for supplementary information adopted with a specific timetable.
Nulojix - belatacept - EMEA/H/C/002098/II/0082/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson	
NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0025/G Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.
Obizur - susoctocog alfa - EMEA/H/C/002792/II/0047/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop	Positive Opinion adopted by consensus on 27.10.2022.

Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 01.09.2022.	
PREVYMIS - letermovir - EMEA/H/C/004536/II/0028/G, Orphan Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 01.09.2022.	
Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0031/G Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Jean-Michel Race Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 07.07.2022.	Positive Opinion adopted by consensus on 27.10.2022.
Reblozyl - luspatercept - EMEA/H/C/004444/II/0013, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphy	
Remsima - infliximab - EMEA/H/C/002576/II/0117/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 29.09.2022.	
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0025/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder Opinion adopted on 20.10.2022. Request for Supplementary Information adopted on 15.09.2022.	Positive Opinion adopted by consensus on 20.10.2022.
SARCLISA - isatuximab - EMEA/H/C/004977/II/0017/G sanofi-aventis groupe, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 13.10.2022.	
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0059/G GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.
Somavert - pegvisomant -	

EMEA/H/C/000409/II/0104 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race	
Spikevax - elasomeran - EMEA/H/C/005791/II/0084/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "B.I.a.6.a (Type II): Addition of a new strain (Omicron BA.4-5) resulting in a new Spikevax bivalent Original/Omicron BA.4-5 (50 µg elasomeran/50 µg davesomeran)/mL 0.1 mg/mL dispersion for injection presentation (2.5 mL multidose vial containing 5 doses). The Annex A, the SmPC, the Annex II, the labelling and the Package Leaflet are updated accordingly. Opinion adopted on 19.10.2022.	Positive Opinion adopted by consensus on 19.10.2022. See 9.1
Spikevax - elasomeran - EMEA/H/C/005791/II/0087/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop	
Terrosa - teriparatide - EMEA/H/C/003916/II/0026/G Gedeon Richter Plc., Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 29.09.2022.	
TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0016/G Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 27.10.2022.	Positive Opinion adopted by consensus on 27.10.2022.
Tysabri - natalizumab - EMEA/H/C/000603/II/0133 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 20.10.2022. Request for Supplementary Information adopted on 08.09.2022.	Positive Opinion adopted by consensus on 20.10.2022.
Vimizim - elosulfase alfa - EMEA/H/C/002779/II/0039, Orphan BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 27.10.2022.	Request for supplementary information adopted with a specific timetable.
Vydura - rimegepant - EMEA/H/C/005725/II/0002/G	Request for supplementary information adopted with a specific timetable.

Biohaven Pharmaceutical Ireland DAC, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 20.10.2022.	
Xofigo - radium-223 - **EMEA/H/C/002653/II/0047** Bayer AG, Rapporteur: Janet Koenig	
WS2275/G **GONAL-f-** **EMEA/H/C/000071/WS2275/0156/G** **Pergoveris-** **EMEA/H/C/000714/WS2275/0078/G** Merck Europe B.V., Lead Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 07.07.2022.	Positive Opinion adopted by consensus on 27.10.2022.
WS2340/G **Fluenz Tetra-** **EMEA/H/C/002617/WS2340/0119/G** **Pandemic influenza vaccine H5N1** **AstraZeneca-** **EMEA/H/C/003963/WS2340/0053/G** AstraZeneca AB, Lead Rapporteur: Christophe Focke	
WS2344 **Ryzodeg-** **EMEA/H/C/002499/WS2344/0048** **Tresiba-EMEA/H/C/002498/WS2344/0056** **Xultophy-** **EMEA/H/C/002647/WS2344/0044** Novo Nordisk A/S, Lead Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 27.10.2022.	Request for supplementary information adopted with a specific timetable.
WS2346/G **Blitzima-** **EMEA/H/C/004723/WS2346/0059/G** **Truxima-** **EMEA/H/C/004112/WS2346/0062/G** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.
WS2347/G **Infanrix hexa-** **EMEA/H/C/000296/WS2347/0318/G** GlaxoSmithkline Biologicals SA, Lead	Positive Opinion adopted by consensus on 20.10.2022.

Rapporteur: Christophe Focke Opinion adopted on 20.10.2022.	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adtralza - tralokinumab - EMEA/H/C/005255/II/0001 LEO Pharma A/S, Rapporteur: Jayne Crowe, "C.I.4 Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with cytochrome P450 and CYP substrates based on final results from study ECZTRA 4 (LP0162-1342). This is an open-label drug–drug interaction trial to investigate the effects of tralokinumab on the pharmacokinetics of selected CYP substrates in adult subjects with moderate-to-severe atopic dermatitis. In addition, the MAH took the opportunity make editorial changes to sections 4.8, 6.5 and 9 of SmPC." Opinion adopted on 20.10.2022. Request for Supplementary Information adopted on 22.04.2022, 16.12.2021.	Positive Opinion adopted by consensus on 20.10.2022.
Alecensa - alectinib - EMEA/H/C/004164/II/0042 Roche Registration GmbH, Rapporteur: Filip Josephson, "Submission of the final report from study JO28928 (J-ALEX) a Randomized Phase III Open-Label Study Comparing the Efficacy and Safety of Crizotinib and CH5424802 in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer." Opinion adopted on 27.10.2022.	Positive Opinion adopted by consensus on 27.10.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0145 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "To update sections 4.2, 4.8 and 5.1 of the SmPC in order to add recommendations and data for subsequent and booster doses based on real world evidence (RWE) data as well as interim study results from both sub-study E (SSE) and sub-study D (SSD) C4591031 following procedure II/0140 assessment. The Package Leaflet is updated accordingly." Opinion adopted on 27.10.2022.	Positive Opinion adopted by consensus on 27.10.2022.

Darzalex - daratumumab - EMEA/H/C/004077/II/0062, Orphan Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, "Update of section 4.8 of the SmPC in order to add COVID-19 to the list of adverse drug reactions (ADRs) with frequency uncommon, based on a pooled dataset from the following interventional studies 4767414MMY2004, 54767414MMY3003, 54767414MMY3006, 54767414MMY3008, and 54767414MMY3013. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 20.10.2022, 15.09.2022.	Request for supplementary information adopted with a specific timetable.
Dificlir - fidaxomicin - EMEA/H/C/002087/II/0049 Tillotts Pharma GmbH, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC in order to introduce a new posology regimen based on final results from EXTEND study - A Phase IIIb/IV Randomized, Controlled, Open-Label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium difficile Infection in an Older Population. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 21.07.2022.	
JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0053/G Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to introduce an heterologous booster dose of Jcovden following priming with another adenoviral vector-based vaccine and an inactivated whole virion COVID-19 vaccine based on literature evidence from studies COV-BOOST and RHH-01, respectively. Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of JCOVDEN as homologous and heterologous booster dose based on data from studies COV2008, a randomised, double-blind Phase 2 Study and literature evidence from studies COV-BOOST, RHH-001 and DMID 21-0012. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted	See 9.1

on 21.07.2022.	
Kesimpta - ofatumumab - EMEA/H/C/005410/II/0007 Novartis Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 5.1 and 5.2 of the SmPC in order to add information on the pharmacologic profile of ofatumumab subcutaneous administration to properly evaluate and group Kesimpta into the therapeutic landscape of Multiple Sclerosis based on feedback from the German and other HTA bodies, requiring additional information on the pharmacologic profile of ofatumumab (s.c.) to adequately inform payors and prescribers." Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.
Nerlynx - neratinib - EMEA/H/C/004030/II/0029 Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of section 5.2 of the SmPC in order to add information on distribution and on the effect of neratinib on CYP substrates based on non-clinical studies XT218036 and 20325317; study XT218036 was designed to evaluate neratinib as a substrate of the human transporters OATP1B1 and OATP1B3 and study 20325317 objective was to determine the inactivation kinetic constants (kinact and KI) of Neratinib and M6 for the human cytochrome P450 (CYP) isoenzymes 2B6 and 3A4 using pooled human liver microsomes (HLM). In addition, the MAH is also taking this opportunity to introduce editorial changes."	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0017 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of the final report from study in vivo efficacy of Pf-07321332 as a single agent or in combination with ritonavir in Balb/C Mouse-Adapted SARS-CoV-2 Model. The objective of this study was to evaluate whether Ritonavir has in vivo antiviral activity against SARS-CoV-2 and whether combination of Ritonavir with PF-07321332 increased the exposure of PF-07321332 in the mouse model and further decreased viral lung replication."	

Request for Supplementary Information adopted on 01.09.2022.	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0026/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising four type II variations as follows: - Update of sections 4.6, 5.1 and 5.3 in order to update the latest non-clinical virology and toxicology data based on Phase 2/3 studies C4671002, C4671005 and C4671006 and the pre- and postnatal development study report 21GR149. - Update of section 5.2 in order to update pertinent clinical pharmacology information based on completed clinical pharmacology studies with Paxlovid in both healthy participants (Phase 1 studies C4671008, C4671012, C4671013, C467104, C4671015, C4671019) and also participants with mild-to-moderate COVID-19 (Pivotal Phase 2/3 Study C4671005) and final PopPK report (PMAR-EQDD-C467a-DP4-1323). - Update of sections 4.8 and 5.1 in order to include final clinical efficacy and safety data based on the pivotal C4671005 (REC35) study. - Update of sections 4.8 and 5.1 in order to include final clinical efficacy and safety data based on the supportive C4671006 study and interim clinical efficacy and safety data based on the supportive C4671002 (REC36) study. The Package Leaflet is updated accordingly. In addition, the MAH is also taking this opportunity to introduce editorial changes."	
Piqray - alpelisib - EMEA/H/C/004804/II/0013 Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of the SmPC sections 4.6 and 5.3 in order to add fertility data based on studies 2070119 "BYL719: Oral (Gavage) Study of Fertility in the Male Rat" and 2070120 "BYL719: Oral (Gavage) Study of Fertility and Early Embryonic Development in the Female Rat"." Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.

Request for Supplementary Information adopted on 21.07.2022.	
Regkirona - regdanvimab - EMEA/H/C/005854/II/0008 Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update the information on the clinical resistance data based on final genotype and phenotype results from study CT-P59 3.2 Part 2; this is a Phase 2/3, randomized, parallel-group, placebo-controlled, double-blind study to evaluate the efficacy and safety of CT-P59 in combination with standard of care in outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection."	
Retsevmo - selpercatinib - EMEA/H/C/005375/II/0017 Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, "Update of section 4.5 of the SmPC in order to update drug-drug interaction information based on the final results from study J2G-MC-JZJV; this is a phase 1, single-center, open-label, drug-drug interaction (DDI) study to investigate the effect of selpercatinib on the pharmacokinetic profiles of dabigatran, a P-glycoprotein (P-gp) substrate, in healthy volunteers. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 06.10.2022.	
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0054 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Update of section 4.5 of the SmPC based on final results from study ZOSTER-059; this is a Phase IIIB, open label, randomised, controlled study to evaluate the immunogenicity, safety and reactogenicity of Shingrix when co-administered with Prevenar 13 in adults ≥ 50 years of age. In addition, the MAH took the opportunity to update section 4.5 of the SmPC to update the existing statement to specify the incidence percentages of fever and shivering upon co-administration of Shingrix with PPV23 based on study ZOSTER-035." Opinion adopted on 20.10.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 20.10.2022.

on 23.06.2022.	
SonoVue - sulfur hexafluoride - EMEA/H/C/000303/II/0049 Bracco International B.V., Rapporteur: Alexandre Moreau, "Update of sections 4.1, 4.4 and 5.1 of the SmPC based on final results from study BR1-145 listed as a PAES in the Annex II; this is an observational, retrospective, multicentre, comparative study conducted in patients below 18 years of age who had undergone a VUS exam with intravesically administered SonoVue/Lumason or a VCUG exam as part of their standard of care for evaluation of known or suspected VUR." Request for Supplementary Information adopted on 23.06.2022.	
Trecondi - treosulfan - EMEA/H/C/004751/II/0016, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 01.09.2022, 23.06.2022.	
Veklury - remdesivir - EMEA/H/C/005622/II/0042 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of section 5.1 to provide in vitro data on the antiviral activity of remdesivir against the Omicron subvariants BA.2.12.1, BA.4 and BA.5 following procedure II/0034/G based on in vitro study "Remdesivir Antiviral Activity against Omicron Subvariants BA.2.12.1, BA.4, and BA.5 in A549-hACE2-TMPRSS2 Cells"."	
Venclyxto - venetoclax - EMEA/H/C/004106/II/0042 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Update of section	Positive Opinion adopted by consensus on 20.10.2022.

5.1 of the SmPC in order to update data supporting the efficacy of the combined regimen of obinutuzumab and venetoclax (VEN+G; also known as GDC-0199 or ABT-199) versus obinutuzumab plus chlorambucil (GClb) in previously untreated CLL patients based on final results from study BO25323/CLL14; this is a prospective, open-label, multicenter randomized phase 3 trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax (GDC-0199/ABT-199) versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Opinion adopted on 20.10.2022. Request for Supplementary Information adopted on 15.09.2022.	
VEYVONDI - vonicog alfa - EMEA/H/C/004454/II/0026 Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add 'headache' to the list of adverse drug reactions (ADRs) with frequency very common and to update information based on final results from study 071301 and other available data; study 071301 is a prospective, phase 3, open-label, international multicenter study on efficacy and safety of prophylaxis with rVWF in severe von Willebrand disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI and bring it in line with the latest QRD template." Request for Supplementary Information adopted on 20.10.2022.	Request for supplementary information adopted with a specific timetable.
Xarelto - rivaroxaban - EMEA/H/C/000944/II/0097 Bayer AG, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add ´eosinophilic pneumonia´ to the list of adverse drug reactions (ADRs) with frequency 'very rare', based on post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the	Positive Opinion adopted by consensus on 20.10.2022.

Package Leaflet." Opinion adopted on 20.10.2022.	
Xevudy - sotrovimab - **EMEA/H/C/005676/II/0010/G** Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "C.I.4: Update of sections 4.4 and 5.1 of the SmPC based on results from study reports PC-22-0108 on the in vitro activity of sotrovimab against Omicron spike variants encoding epitope substitutions in a pseudotyped virus assay, PC-22-0116 on the in vitro activity of sotrovimab against the SARS-CoV-2 XD variant in a live virus assay, PC-22-0117 on the in vitro activity of sotrovimab against the SARS-CoV-2 Omicron BA.2.12.1, BA.4 and BA.5 variants in a live virus assay, and PC-22-0124 on the in vitro activity of sotrovimab against the Omicron BA.2.75 spike variant in a pseudotyped virus assay. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.13: Submission of the final study report PC-22-0101 on the in vivo activity of S309 encoding the hamster Fc region in a Syrian golden hamster model of SARS-CoV-2 Omicron BA.2 infection. C.I.13: Submission of the final study report PC-22-0126 on the in vivo activity of VIR-7831-WT in a Syrian golden hamster model of SARS-CoV-2 Omicron BA.5. infection."	
WS2259 **DuoPlavin-** **EMEA/H/C/001143/WS2259/0063** **Iscover-** **EMEA/H/C/000175/WS2259/0149** **Plavix-EMEA/H/C/000174/WS2259/0147** sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, "Update of section 4.4 of the SmPC in order to update an existing warning on 'Bleeding and haematological disorders' by adding a statement on triple antiplatelet therapy (clopidogrel + aspirin + dipyridamole) for stroke secondary prevention. The Package Leaflet is updated accordingly." Opinion adopted on 20.10.2022. Request for Supplementary Information adopted on 21.07.2022.	Positive Opinion adopted by consensus on 20.10.2022.
WS2342/G **Prezista-**	

EMEA/H/C/000707/WS2342/0119/G **Rezolsta-** **EMEA/H/C/002819/WS2342/0049/G** **Symtuza-** **EMEA/H/C/004391/WS2342/0046/G** Janssen-Cilag International N.V., Lead Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'crystal nephropathy' to the list of adverse drug reactions (ADRs) with frequency rare based on recent post-marketing data; the Package Leaflets are updated accordingly. In addition, the MAH proposes to update sections 4.4 and 4.6 of the SmPC in order to implement the recommendation of the CHMP to remove the disease information relating to sexual transmission of HIV and to amend the sections related to breast-feeding; the Package Leaflets are updated accordingly." Request for Supplementary Information adopted on 29.09.2022.	
WS2343 **Ozempic-** **EMEA/H/C/004174/WS2343/0033** **Rybelsus-** **EMEA/H/C/004953/WS2343/0028** Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege, "Submission of an updated final report from study NN9535-4386 (SUSTAIN-11) in order to amend an error. This study was listed as a category 3 study in the RMP and was previously assessed in procedure EMEA/H/C/004174/II/WS/2141. This is a Phase IIIb A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group, randomised trial in subjects with type 2 diabetes to evaluate the effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes." Opinion adopted on 20.10.2022.	Positive Opinion adopted by consensus on 20.10.2022.
WS2358 **Elebrato Ellipta-** **EMEA/H/C/004781/WS2358/0028** **Trelegy Ellipta-** **EMEA/H/C/004363/WS2358/0025** GlaxoSmithKline Trading Services Limited, Lead Rapporteur: Finbarr Leacy, "Update of section	

4.8 of the SmPC in order to add 'urinary retention' and 'dysuria' to the list of adverse drug reactions (ADRs) with frequency rare; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring it in line with the latest QRD template."	

B.5.3. CHMP-PRAC assessed procedures

Beovu - brolucizumab - EMEA/H/C/004913/II/0018 Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.2 and 5.1 of the SmPC in order to introduce an alternative posology regimen for wet AMD and update information based on modelling and simulation studies; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted."	
EVUSHELD - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0003 AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to change the posology recommendations in the pre-exposure prophylaxis indication based on study TACKLE (D8851C00001). The Package Leaflet is updated accordingly. The RMP version 2 has also been submitted." Request for Supplementary Information adopted on 13.10.2022.	See 9.1
HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0078 Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety data in paediatric population based on final results from study 161504 – Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases, listed as a category 3 study in the RMP. This is a paediatric interventional Phase 4 study performed to acquire additional data on safety, tolerability and immunogenicity of HyQvia in paediatric	Positive Opinion adopted by consensus on 27.10.2022.

(age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD). In addition, the MAH is taking this opportunity to update Annex II-D of the PI following procedure EMEA/H/C/002491/II/0070/G, and to remove the statement that this medicinal product is subject to additional monitoring from the SmPC and package leaflet following the fulfilment of the PASS 161302. The RMP version 13.1 has also been adopted." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 07.07.2022.	
IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/II/0059, Orphan CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update information and amend the frequencies of adverse drug reactions (ADRs) based on the final results from study CSL654_3003 listed as a category 3 study in the RMP; this is an open-label, multicentre, uncontrolled study to evaluate the safety, pharmacokinetics and clinical response of rIX-FP with regard to the prevention and treatment of bleeding in previously untreated patients (PUPs) with Haemophilia B. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 27.10.2022, 10.06.2022.	Request for supplementary information adopted with a specific timetable.
Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0036 Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 27.10.2022.	Request for supplementary information adopted with a specific timetable.
Imnovid - pomalidomide - EMEA/H/C/002682/II/0047, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Monica Martinez Redondo, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to	Request for supplementary information adopted with a specific timetable.

harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The updated RMP version 16 was provided." Request for Supplementary Information adopted on 27.10.2022.	
Jorveza - budesonide - EMEA/H/C/004655/II/0015, Orphan Dr. Falk Pharma GmbH, Rapporteur: Martina Weise, PRAC Rapporteur: Zane Neikena, "Update of section 4.8 of the SmPC in order to update the list of adverse reactions based on final results from the long-term maintenance study BUL-2/EER; this is a double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 3.0 has also been submitted. The MAH also submitted the final report of study BUL-6/BIO, which was previously assessed within the scope of extension EMEA/H/C/004655/X/0007/G as applicant's response to CHMP Day 120 List of Questions." Request for Supplementary Information adopted on 15.09.2022, 19.05.2022.	
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0042, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, "Submission of the updated protocol from study SHP634-403 listed as a Specific Obligation in the Annex II of the Product Information with twice-daily (BID) as the proposed alternative dosing regimen to be	

evaluated. This is a Randomized, 2-Arm, Double-Blind, Phase 4 Study to Evaluate Once Daily (QD) Versus Twice Daily (BID) Administration of Recombinant Human Parathyroid Hormone (rhPTH[1-84]; NATPARA) for the Treatment of Adults with Hypoparathyroidism (HPT). The Annex II and the RMP (submitted version 3.4) are updated accordingly." Request for Supplementary Information adopted on 21.07.2022.	
NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0057, Orphan MediWound Germany GmbH, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, "Submission of the 24-months' CSR addendum of the MW2010-03-02 (DETECT) category 1 study; a multicentre, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to gel vehicle and compared to standard of care. The provision of the CSR addresses the post-authorisation measure ANX 001.7. An updated RMP version 8.0 was provided as part of the application."	
Revlimid - lenalidomide - EMEA/H/C/000717/II/0123 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones. The updated RMP version 38 was provided."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 27.10.2022.	
RINVOQ - upadacitinib - EMEA/H/C/004760/II/0020/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Hypersensitivity' and add it to the list of adverse drug reactions (ADRs) with frequency not known. The MAH also proposed to update section 4.8 of the SmPC in order to add 'Non-Melanoma Skin Cancer (NMSC)' to the list of adverse drug reactions (ADRs) with frequency uncommon. The Package Leaflet has been updated accordingly. The RMP version 9.0 has also been submitted." Request for Supplementary Information adopted on 15.09.2022, 10.06.2022.	
Thalidomide BMS - thalidomide - EMEA/H/C/000823/II/0076 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones, and to make some editorial changes in the labelling. The updated RMP version 20 was provided." Request for Supplementary Information adopted on 27.10.2022.	Request for supplementary information adopted with a specific timetable.
Trecondi - treosulfan - EMEA/H/C/004751/II/0012, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update	Positive Opinion adopted by consensus on 27.10.2022.

of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with regards to CYP3A4, CYP2C19 and P-gp including physiologically based pharmacokinetic (PBPK) modelling. Version 1.0 of the RMP has also been submitted." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 07.07.2022.	
Vumerity - diroximel fumarate - EMEA/H/C/005437/II/0005 Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Submission of the final report from study ALK8700-A301, A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis listed as a category 3 study in the RMP. This is a multicentre, open-label study to evaluate the long-term safety, tolerability, and treatment effect over time of DRF administered for up to 96 weeks in adult participants with RRMS. The RMP version 1.2 has been agreed." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 01.09.2022.	Positive Opinion adopted by consensus on 27.10.2022.
Vyndaqel - tafamidis - EMEA/H/C/002294/II/0081, Orphan Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 5.1 of the SmPC in order to update information based on final results from study B3461029 listed as a Specific Obligation in the Annex II of the Product Information. This is a non-interventional PASS sub-study evaluating effects of tafamidis on disease progression in patients with non-Val30Met mutations and symptomatic neuropathy. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 15.09.2022, 21.07.2022.	

WS2187 **OPDIVO-** **EMEA/H/C/003985/WS2187/0121** **Yervoy-EMEA/H/C/002213/WS2187/0098** Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.8 of the SmPC in alignment with the recommendations made by the CHMP to revise the pooling approach used to describe irARs and tabulated summaries of ADRs following II/0096. Individual study data included within this application has been previously reviewed by the CHMP. The updated Opdivo RMP version 29.0 and Yervoy RMP version 37.0 have also been submitted. The MAH took the opportunity to introduce editorial changes. The Package Leaflet was updated accordingly." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 01.09.2022.	Positive Opinion adopted by consensus on 27.10.2022.

B.5.4. PRAC assessed procedures

PRAC Led **Brintellix - vortioxetine -** **EMEA/H/C/002717/II/0037** H. Lundbeck A/S, PRAC Rapporteur: Jo Robays, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study PASS 16034N listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study (PASS) of vortioxetine in Europe - An analysis of European automated healthcare databases. The RMP version 4.0 has also been submitted." Request for Supplementary Information adopted on 27.10.2022, 07.07.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Kaletra - lopinavir / ritonavir -** **EMEA/H/C/000368/II/0193** AbbVie Deutschland GmbH & Co. KG, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Jean-Michel Race, "Submission of the final report from study P19-106 listed as a category 3 study in the RMP. This is a European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) observational study	Positive Opinion adopted by consensus on 27.10.2022.

assessing the safety and effectiveness of Kaletra oral solution in children aged 14 days to 2 years with human immunodeficiency virus 1 (HIV-1) infection in Europe. The RMP version 10.0 has also been submitted." Opinion adopted on 27.10.2022.	
PRAC Led **Menveo - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/II/0112** GSK Vaccines S.r.l, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 10 in order to remove several safety concerns." Opinion adopted on 27.10.2022.	Positive Opinion adopted by consensus on 27.10.2022.
PRAC Led **SCENESSE - afamelanotide - EMEA/H/C/002548/II/0042, Orphan** Clinuvel Europe Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP in order to update the allergy and hypersensitivity risk from potential to identified, following reported cases of positive allergy test results, confirming the causal association between the allergies to afamelanotide. Consequently, the RMP has been revised to reclassify the important potential risk Allergy and hypersensitivity to important identified risk." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 01.09.2022.	Positive Opinion adopted by consensus on 27.10.2022.
PRAC Led **Spikevax - elasomeran - EMEA/H/C/005791/II/0077** Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Update of section 4.8 of the SmPC to include 'Urticaria' as an adverse reaction, with the frequency 'Uncommon', as requested by the PRAC in the 13th Safety Summary Report (EMEA/H/C/005791/MEA/011.12). The Package Leaflet is updated accordingly." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 27.10.2022.

on 29.09.2022.	
PRAC Led **Stelara - ustekinumab - EMEA/H/C/000958/II/0091** Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Update of the SmPC sections 4.4, 4.5 and 4.6 with recommendation not to administer live vaccines to infants for six months following birth unless ustekinumab infant serum levels are undetectable or there is clear clinical benefit for the individual infant. The update follows assessment of the final safety registry report of CNTO1275PSO4007 "Pregnancy Research Initiative: Exposure to ustekinumab during pregnancy: A review and analysis of birth outcomes from the Swedish, Danish, and Finnish medical birth registers." Consequently, the PL and the RMP version 22.1 have also been updated. Additionally, minor editorial changes and updates to the list of representatives were introduced." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 10.06.2022, 10.02.2022.	Positive Opinion adopted by consensus on 27.10.2022.
PRAC Led **SYLVANT - siltuximab - EMEA/H/C/003708/II/0038, Orphan** EUSA Pharma (Netherlands) B.V., PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of the report from study ACCELERATE (Advancing Castleman Care with an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients with Castleman Disease - NCT02817997 listed as an obligation in the Annex II of the Product Information. This is a study report to cover the data collected for 100 patients over a 5 year period in the ACCELERATE Registry study to collect information or patients with Castleman's Disease who are candidates to receive Sylvant or are currently receiving treatment with Sylvant. The Annex II is updated accordingly." Request for Supplementary Information adopted on 27.10.2022.	Request for supplementary information adopted with a specific timetable.

PRAC Led **VIZAMYL - flutemetamol (18F) - EMEA/H/C/002557/II/0029** GE Healthcare AS, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study (GE067-027) listed as a category 3 study in the RMP in addition to a comprehensive root-cause analysis on the contributing factors having an impact on reader performance as requested by PRAC. This is a non-interventional post-authorisation safety study (PASS) to evaluate the effectiveness of VIZAMYL reader training in Europe. The RMP version 3.4 has also been agreed and was updated to reflect the completion of study GE067-028, previously assessed in MEA 003.3." Opinion adopted on 27.10.2022. Request for Supplementary Information adopted on 01.09.2022, 10.06.2022.	Positive Opinion adopted by consensus on 27.10.2022.

B.5.5. CHMP-CAT assessed procedures

CARVYKTI - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0002, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus,	
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0031, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 09.09.2022.	
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0034/G, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Jan Mueller-Berghaus	

B.5.6. CHMP-PRAC-CAT assessed procedures

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0033/G, Orphan, ATMP	

Novartis Europharm Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to introduce additional guidance on liver function laboratory tests and monitoring before and after infusion and update information based on new safety information on the topic of acute liver failure (ALF) following two reports of fatal ALF. Update of sections 4.2 and 4.4 of the SmPC in order to provide additional guidance relevant to patient's overall health status prior to dosing and to strengthen the existing description and guidance on systemic immune response. Update of section 4.4 of the SmPC in order to indicate prompt attention to thrombotic microangiopathy (TMA) and to reflect the risk of life-threatening or fatal outcomes. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update the Annex II."	

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2243/G **Herceptin-** **EMEA/H/C/000278/WS2243/0184/G** **MabThera-** **EMEA/H/C/000165/WS2243/0193/G** Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus,	
WS2278/G **Copalia-** **EMEA/H/C/000774/WS2278/0125/G** **Copalia HCT-** **EMEA/H/C/001159/WS2278/0100/G** **Dafiro-** **EMEA/H/C/000776/WS2278/0129/G** **Dafiro HCT-** **EMEA/H/C/001160/WS2278/0102/G** **Exforge-** **EMEA/H/C/000716/WS2278/0124/G** **Exforge HCT-** **EMEA/H/C/001068/WS2278/0099/G** Novartis Europharm Limited, Lead Rapporteur:	Positive Opinion adopted by consensus on 27.10.2022.

Thalia Marie Estrup Blicher
Opinion adopted on 27.10.2022.
Request for Supplementary Information adopted on 23.06.2022.

WS2308/G
AZILECT-
EMEA/H/C/000574/WS2308/0090/G
Rasagiline ratiopharm-
EMEA/H/C/003957/WS2308/0022/G
Teva B.V., Lead Rapporteur: Bruno Sepodes
Request for Supplementary Information adopted on 08.09.2022.

WS2315/G
Biktarvy-
EMEA/H/C/004449/WS2315/0051/G
Descovy-
EMEA/H/C/004094/WS2315/0058/G
Genvoya-
EMEA/H/C/004042/WS2315/0084/G
Odefsey-
EMEA/H/C/004156/WS2315/0055/G
Vemlidy-
EMEA/H/C/004169/WS2315/0041/G
Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes,
Request for Supplementary Information adopted on 06.10.2022.

WS2331
Descovy-
EMEA/H/C/004094/WS2331/0059
Emtriva-
EMEA/H/C/000533/WS2331/0140
Odefsey-
EMEA/H/C/004156/WS2331/0056
Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, "To update sections 4.4 and 4.6 of the SmPC to implement modifications of the HIV SmPC/PL to update wording related to the risk of HIV transmission in accordance with the January 2022 CHMP adoption of an update to the Product Information for all approved HIV products, recommending the removal of the disease information relating to sexual transmission of HIV and amendment of the sections relating to breast-feeding.
The MAH has taken the opportunity to update the contact details of the local representative listed in the Package Leaflet for Estonia, Latvia, Lithuania and Romania. An editorial change has

also been made to the SmPC and Patient Information Leaflet for Emtriva 10 mg/ml oral solution to correct an error in the sodium content.”	
WS2337/G **Copalia-** **EMEA/H/C/000774/WS2337/0126/G** **Dafiro-** **EMEA/H/C/000776/WS2337/0130/G** **Exforge-** **EMEA/H/C/000716/WS2337/0125/G** Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, “C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107. C.I.11.a - To update Annex II to reflect the fulfilment of Condition B, as set out by the Commission Decision as an outcome of the assessment for the impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group.” Request for Supplementary Information adopted on 08.09.2022.	
WS2338 **Copalia HCT-** **EMEA/H/C/001159/WS2338/0102** **Dafiro HCT-** **EMEA/H/C/001160/WS2338/0104** **Exforge HCT-** **EMEA/H/C/001068/WS2338/0101** Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, “C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107.” Request for Supplementary Information adopted on 08.09.2022.	
WS2348 **Ongentys-** **EMEA/H/C/002790/WS2348/0052** **Ontilyv-EMEA/H/C/005782/WS2348/0007**	

Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise	
WS2379/G **Lixiana-** **EMEA/H/C/002629/WS2379/0039/G** **Roteas-** **EMEA/H/C/004339/WS2379/0026/G** Daiichi Sankyo Europe GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro	

B.5.9. Information on withdrawn type II variation / WS procedure

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

vamorolone - EMEA/H/C/005679, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, Treatment of Duchenne muscular dystrophy (DMD)	
cabotegravir - EMEA/H/C/005756 pre-exposure prophylaxis of HIV-1 infection	
recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e - EMEA/H/C/006054 active immunisation or the prevention of lower respiratory tract disease (LRTD)	**Accelerated review**
lebrikizumab - EMEA/H/C/005894 Treatment of moderate-to-severe atopic dermatitis in adults and adolescents	
eribulin - EMEA/H/C/006134 treatment of breast cancer and liposarcoma	
epcoritamab - EMEA/H/C/005985, Orphan AbbVie Deutschland GmbH & Co. KG, treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	
leniolisib - EMEA/H/C/005927, Orphan Pharming Technologies B.V., Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)	**Accelerated review**
epinephrine - EMEA/H/C/006139 Treatment of allergic reactions (anaphylaxis)	

and idiopathic or exercise induced anaphylaxis	
ranibizumab - EMEA/H/C/006055 treatment of neovascular age-related macular degeneration (AMD)	

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

COMIRNATY - tozinameran - EMEA/H/C/005735/X/0147 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, "Extension application to add a new strength of 5/5 µg/dose for the Comirnaty Original/Omicron BA.4-5 concentrate for dispersion for injection for children aged between 5 to 11 years. The RMP (version 7.2) is updated in accordance."	See 9.1

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

niraparib / abiraterone acetate - EMEA/H/C/005932 treatment of adult patients with prostate cancer List of Questions adopted on 15.09.2022.
eculizumab - EMEA/H/C/005652 treatment of paroxysmal nocturnal haemoglobinuria List of Questions adopted on 21.07.2022.
trastuzumab - EMEA/H/C/005769 treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC) List of Questions adopted on 19.05.2022.
raltegravir potassium - EMEA/H/C/005813 treatment of human immunodeficiency virus (HIV-1) List of Questions adopted on 21.07.2022.
ivosidenib - EMEA/H/C/005936, Orphan Les Laboratoires Servier, treatment of acute myeloid leukaemia and treatment of metastatic cholangiocarcinoma List of Questions adopted on 21.07.2022.
ivosidenib - EMEA/H/C/006174, Orphan Les Laboratoires Servier, treatment of acute myeloid leukaemia List of Questions adopted on 21.07.2022.

B.6.4. Annual Re-assessments: timetables for adoption

Myalepta - metreleptin -
EMEA/H/C/004218/S/0030, Orphan
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Adam Przybylkowski

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

BLINCYTO - blinatumomab -
EMEA/H/C/003731/R/0048, Orphan
Amgen Europe B.V., Rapporteur: Alexandre Moreau, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Eva Jirsová

Deltyba - delamanid -
EMEA/H/C/002552/R/0062, Orphan
Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jo Robays

Dzuveo - sufentanil -
EMEA/H/C/004335/R/0009
Laboratoire Aguettant, Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Adam Przybylkowski

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein -
EMEA/H/C/005737/R/0063
Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga

JEMPERLI - dostarlimab -
EMEA/H/C/005204/R/0017
GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Lojuxta - lomitapide -
EMEA/H/C/002578/R/0054
Amryt Pharmaceuticals DAC, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Lonquex - lipegfilgrastim -
EMEA/H/C/002556/R/0077
Teva B.V., Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC

Rapporteur: Kirsti Villikka

Myalepta - metreleptin -
EMEA/H/C/004218/R/0031, Orphan
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Adam Przybylkowski

Natpar - parathyroid hormone -
EMEA/H/C/003861/R/0046, Orphan
Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Rhea Fitzgerald

Nerlynx - neratinib -
EMEA/H/C/004030/R/0031
Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Pemazyre - pemigatinib -
EMEA/H/C/005266/R/0007, Orphan
Incyte Biosciences Distribution B.V., Rapporteur: Alexandre Moreau, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Menno van der Elst

RXULTI - brexpiprazole -
EMEA/H/C/003841/R/0014
Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Lucia Kuráková

Tegsedi - inotersen -
EMEA/H/C/004782/R/0035, Orphan
Akcea Therapeutics Ireland Limited, Rapporteur: Martina Weise, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Rhea Fitzgerald

Trazimera - trastuzumab -
EMEA/H/C/004463/R/0020
Pfizer Europe MA EEIG, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Sol Ruiz, PRAC Rapporteur: Brigitte Keller-Stanislawski

Verkazia - ciclosporin -
EMEA/H/C/004411/R/0021, Orphan
Santen Oy, Duplicate, Duplicate of IKERVIS, Rapporteur: Jayne Crowe, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Jan Neuhauser

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0013/G	Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Extension of indication to include treatment of moderate to severe pain associated with endometriosis for RYEQO in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis, based on final results from studies MVT-601-3101 and MVT-601-3102 and final results up to 104 weeks from study MVT-601-3103. Studies 3101 and 3102 are pivotal, phase III, randomised, double-blind, placebo-controlled, safety and efficacy studies to evaluate relugolix with E2 and NETA as a combination therapy for pain associated with endometriosis. Study 3103 is an open-label extension study including patients who completed one of the two pivotal studies and met the eligibility criteria, regardless of their treatment assignment in the pivotal studies. In the extension part all patients received relugolix combination therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC were updated. The Package Leaflet is updated in accordance. Update of section 4.5 of the SmPC to update information regarding Drug-Drug Interaction based on final results of DDI studies MVT-601-54, MVT-601-55 and MVT-601-57. Study MVT-601-54 is a 2-part interventional open-label study to assess the potential effects of erythromycin on the PK of the 3 components of Ryeqo. Study MVT-601-55 is an interventional open label fixed single sequence cross-over study to assess whether a 6-hour dose separation is sufficient to mitigate absorption mediated increased exposure to relugolix and study MVT-601-057 is a 2-part study to assess the potential effect of relugolix on the PK of total dabigatran. The updated RMP version (2.0) has also been

submitted. As part of the application, the MAH also requests an extension of the market protection by one additional year."

Valdoxan - agomelatine - EMEA/H/C/000915/II/0051
Les Laboratoires Servier, Rapporteur: Eva Skovlund, PRAC Rapporteur: Pernille Harg, "Extension of indication to include new therapeutic indication in adolescents aged 12 to 17 years for the treatment of moderate to severe major depressive episodes, if depression is unresponsive to psychological therapy alone, for Valdoxan, further to the results of the phase 2 (CL2-20098-075) and phase 3 (CL3-20098-076) paediatric clinical studies included in the Paediatric Investigation Plan number EMEA-001181-PIP-11; As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated.
The Package Leaflet is updated accordingly.
The updated RMP version 25.1 has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Beovu - brolucizumab - EMEA/H/C/004913/II/0019
Novartis Europharm Limited, Rapporteur: Alexandre Moreau

Ervebo - recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0027
Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke

Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0031
Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0061
Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0067
Janssen-Cilag International N.V., Rapporteur:

Christophe Focke

Luminity - perflutren -
EMEA/H/C/000654/II/0042/G
Lantheus EU Limited, Rapporteur: Finbarr Leacy

Nimenrix - meningococcal group A, C, W135 and Y conjugate vaccine -
EMEA/H/C/002226/II/0120/G
Pfizer Europe MA EEIG, Rapporteur: Ingrid Wang

Nivestim - filgrastim -
EMEA/H/C/001142/II/0070/G
Pfizer Europe MA EEIG, Rapporteur: Outi Mäki-Ikola

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda -
EMEA/H/C/005808/II/0034
Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege

Padcev - enfortumab vedotin -
EMEA/H/C/005392/II/0005/G
Astellas Pharma Europe B.V., Rapporteur: Aaron Sosa Mejia

Rapiscan - regadenoson -
EMEA/H/C/001176/II/0041/G
GE Healthcare AS, Rapporteur: Maria Concepcion Prieto Yerro

Ryeqo - relugolix / estradiol / norethisterone acetate -
EMEA/H/C/005267/II/0012
Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik

Spikevax - elasomeran -
EMEA/H/C/005791/II/0087/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop

Zaltrap - aflibercept -
EMEA/H/C/002532/II/0067/G
sanofi-aventis groupe, Rapporteur: Filip Josephson

WS2302/G
Fiasp-
EMEA/H/C/004046/WS2302/0031/G
NovoMix-

EMEA/H/C/000308/WS2302/0112/G
NovoRapid-
EMEA/H/C/000258/WS2302/0142/G
Ryzodeg-
EMEA/H/C/002499/WS2302/0049/G
Novo Nordisk A/S, Lead Rapporteur: Kristina Dunder

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Brintellix - vortioxetine -
EMEA/H/C/002717/II/0038
H. Lundbeck A/S, Rapporteur: Karin Janssen van Doorn, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to include clinically relevant information on the efficacy, safety, tolerability and PK of vortioxetine in the paediatric population based on final results from studies 12709A, 12712A and 12712B.
Study 12709A is an interventional, randomized, double-blind, placebo-controlled, active-reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major Depressive Disorder (MDD) to evaluate efficacy and safety. Whereas studies 12712A and 12712B are 2 open-label, long-term safety and efficacy studies in children and adolescents: one 6-month extension study (study 12712A) to studies 12709A and 12710A, and one 18-month extension study (study 12712B) to study 12712A. The Package Leaflet is updated accordingly."

Calquence - acalabrutinib -
EMEA/H/C/005299/II/0015
AstraZeneca AB, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC based on the interim report of study ACE-CL-007; a randomized, multicenter, open-Label, 3-arm phase 3 study of obinutuzumab in combination with chlorambucil, ACP-196 in combination with obinutuzumab, and ACP-196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia."

COVID-19 Vaccine (inactivated, adjuvanted) Valneva - SARS-CoV-2 virus, strain Wuhan hCoV-19/Italy/INMI1-isl/2020, inactivated -
EMEA/H/C/006019/II/0004
Valneva Austria GmbH, Rapporteur: Andrea

Laslop, "Update of sections 4.2 and 5.1 of the SmPC in order to include a booster dose for adults 18 to 50 years of age based on the interim results from study VLA2001-301 (Booster part); this is a randomized, observer-blind, controlled, superiority study to compare the immunogenicity of COVID-19 Vaccine (inactivated, adjuvanted) Valneva to AZD1222, where participants received a booster dose of COVID-19 vaccine Valneva; the Package Leaflet is updated accordingly."	
Hepcludex - bulevirtide - EMEA/H/C/004854/II/0019, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, "Update of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs) and efficacy information based on interim results from study MYR301 listed as a Specific Obligation in the Annex II of the Product Information; this is a Multicenter, Open-label, Randomized Phase III Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation given the fulfilment of the SOB. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."	
Imfinzi - durvalumab - EMEA/H/C/004771/II/0052 AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, "Update of section 4.2 of the SmPC in order to update the recommendation for dose modification for 'other immune-mediated adverse reactions' as well as immune-mediated encephalitis, meningitis, Guillain-Barré syndrome and myasthenia gravis based on the National Comprehensive Cancer Network (NCCN) guideline recommendations (2022)."	
Myocet liposomal - doxorubicin hydrochloride - EMEA/H/C/000297/II/0070 Teva B.V., Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC, upon request by PRAC following the assessment of EMEA/H/C/PSUSA/00001172/202111, to align the wording with the published CHMP SWP	

advice on the duration of contraception in female patients after cessation of treatment with genotoxic drug. The Package Leaflet has been updated accordingly."	
NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0030 Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, "Submission of 6-month efficacy and safety interim data from the ongoing randomized, observer-blinded, placebo-controlled clinical studies 2019nCoV-501, 2019nCoV-301 and 2019nCoV-302."	
SARCLISA - isatuximab - EMEA/H/C/004977/II/0018/G sanofi-aventis groupe, Rapporteur: Paula Boudewina van Hennik, "C.I.4: Update of sections 4.5, 5.1 and 5.2 of the SmPC in order to update the efficacy and pharmacokinetic data based on final progression-free survival (PFS) efficacy results from IKEMA study (EFC15246) and to introduce the Sebia Hydrashift assay, a validated assay to determine the complete response rate. IKEMA study (EFC15246) is a phase 3 randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines. A.6: Update of section 5.1 of the SmPC in order to update ATC code following amendment by WHO."	
SIRTURO - bedaquiline - EMEA/H/C/002614/II/0051, Orphan Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC in order to update information on breast-feeding based on new literature."	
Supemtek - quadrivalent influenza vaccine (recombinant, prepared in cell culture) - EMEA/H/C/005159/II/0009 Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus, "Update of section 5.1 of the SmPC in order to update the efficacy information based on final results from study VAP00003 listed as a	

category 3 study in the RMP; this is a phase 4, multi-center, modified-cluster randomized study to assess the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine in adults. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0110 MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 4.8 of the SmPC in order to add 'hypersensitivity' and 'anaphylactic reaction' to the list of adverse drug reactions (ADRs) with frequency not known based on the safety assessment of post-marketing reports of hypersensitivity including anaphylactic reactions; the Package Leaflet is updated accordingly."	
Veklury - remdesivir - EMEA/H/C/005622/II/0043 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC in order to update information based on the final virology report (PC-540-2040) for study GS-US-540-9012 in order to fulfil the recommendation by CHMP in the AR for (EMEA/H/C/005622/II/0016); this is a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of RDV in an outpatient setting in participants with confirmed COVID-19 who were at risk for disease progression. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
Velphoro - iron - EMEA/H/C/002705/II/0028 Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC, upon request by the PRAC following the assessment of PSUSA/00010296/202111, to include information on the effect on iron parameters and haemoglobin, based on results from the previously submitted post-hoc analysis of study PA-CL-05A; a Phase 3, open-label, randomised, active-controlled, parallel group, multicentre	

clinical study, and its extension study PA-CL-05B."

Zejula - niraparib - EMEA/H/C/004249/II/0037, Orphan
GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, "Update of section 5.2 of the SmPC in order to update information on absorption based on results from food effect study 3000-01-004; this is an Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumours."

WS2339/G
Keppra- EMEA/H/C/000277/WS2339/0198/G
UCB Pharma S.A., Lead Rapporteur: Karin Janssen van Doorn, "Grouped application comprising two type II variations as follows:
C.I.4 – Update of section 4.4 of the SmPC in order to add a new warning on lack of efficacy or seizure worsening based on the cumulative review of MAH Global Safety database and published literature.
C.I.4 – Update of section 4.8 of the SmPC in order to add a note on obsessive compulsive disorder in the ADR table based on the cumulative review of MAH Global Safety database, clinical studies, data from external spontaneous reporting database and published literature.
The Package Leaflet is updated accordingly.
In addition, the MAH proposes minor editorial changes of the Labelling."

B.6.10. CHMP-PRAC assessed procedures

Rubraca - rucaparib - EMEA/H/C/004272/II/0037
Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.8 and 5.1 of the SmPC in order to update the efficacy and safety information and the list of adverse drug reactions (ADRs) based on the final results from study CO-338-014 (ARIEL 3) listed as a category 1 PAES in the Annex II; this is a phase

3, multicenter, randomized, double-blind, placebo-controlled study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer. The Package Leaflet is updated accordingly. The RMP version 6.4 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

B.6.11. PRAC assessed procedures

B.6.12. CHMP-CAT assessed procedures

Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0019, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang
Abecma - idecabtagene vicleucel - EMEA/H/C/004662/II/0020, Orphan, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang
Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0009, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani
Carvykti - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0005, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Upstaza - eladocagene exuparvovec - EMEA/H/C/005352/II/0004/G, Orphan, ATMP PTC Therapeutics International Limited, Rapporteur: Maura O'Donovan, CHMP Coordinator: Finbarr Leacy

B.6.13. CHMP-PRAC-CAT assessed procedures

Carvykti - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0003, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays , "Update of sections 4.4 and 4.8 of the SmPC in order to update the existing warnings on cytokine release syndrome (CRS), neurologic toxicities and grading of related events and to update the list of adverse drug reactions (ADRs) based on previously reviewed data from studies MMY2001 and MMY2003, and an additional internal characterisation of neurotoxicity risk; the Package Leaflet is updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
Carvykti - ciltacabtagene autoleucel - EMEA/H/C/005095/II/0004/G, Orphan, ATMP Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, PRAC Rapporteur: Jo Robays, "Grouped application comprising two type II variations as follows: - Update of section 4.4 of the SmPC in order to add a new warning on increased risk of severe/fatal COVID-19 infections following COVID-19 signal evaluation from the ongoing study 68284528MMY3002 (CARTITUDE-4) based on a cumulative review of all clinical trials, registries and literature. - Update of section 4.4 of the SmPC in order to add a new warning Risk of severe bleeding in the context of hemophagocytic lymphohistiocytosis syndrome (HLH) following a signal evaluation from the ongoing study 68284528MMY3002 (CARTITUDE-4) based on cumulative review of all clinical trials, registries and literature. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted."	
Libmeldy - atidarsagene autotemcel - EMEA/H/C/005321/II/0011/G, Orphan, ATMP Orchard Therapeutics (Netherlands) B.V., Rapporteur: Carla Herberts, CHMP Coordinator:	

Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Grouped application (Clinical & Quality) consisting of: Type II (C.I.4): Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to remove the option of using bone marrow (BM) as a cellular source for the manufacture of Libmeldy, as a result of an evolution of clinical practices and also to rationalise the manufacture of this highly complex medicinal product; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to remove ANX/002 from the Annex II and to introduce minor editorial changes to the PI. The RMP version 1.3 has also been submitted."

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2364/G **Herceptin-** **EMEA/H/C/000278/WS2364/0185/G** **MabThera-** **EMEA/H/C/000165/WS2364/0194/G** Roche Registration GmbH, Lead Rapporteur: Aaron Sosa Mejia
WS2373 **Copalia HCT-** **EMEA/H/C/001159/WS2373/0103** **Dafiro HCT-** **EMEA/H/C/001160/WS2373/0105** **Exforge HCT-** **EMEA/H/C/001068/WS2373/0102** Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, "To update Annex II to request an extension of the due date for the fulfilment of condition B. In addition, the marketing authorisation holder has taken the opportunity to implement a minor editorial change in the PI for Dafiro HCT."
WS2380/G **Filgrastim Hexal-** **EMEA/H/C/000918/WS2380/0067/G** **Zarzio-** **EMEA/H/C/000917/WS2380/0068/G** Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 4.4 of the SmPC to add information about myelodysplastic

syndrome (MDS) and acute myeloid leukaemia (AML) in patients with breast and lung cancer to align the PI with the PI of the reference product, Neupogen according to the update published by Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) on 4 August 2022. Sections 2 and 3 of the Package Leaflet have been updated accordingly. Additionally, a Type IA variation has been submitted as the MAH proposes to remove pre-filled syringes without a needle safety guard (NSG) from the dossier (EU/1/08/495/009-12, EU/1/08/495/013-16). Finally, some minor editorial changes were introduced to the PI, in particular the ET, FI, IT, MT and RO annexes.”	

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 07-10 November 2022 CHMP plenary

G.2.2. List of procedures starting in November 2022 for December 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address